Metabolic research
AOD-9604
Lyophilized metabolic research compound
AOD-9604 is a modified fragment of human growth hormone 176-191 studied in GH-fragment and lipid-metabolism signaling models.
Support can confirm any currently available COAs or batch documentation for this product.
Request available documentsConfirm an optional email signup to receive a single-use 10% welcome code.
Get catalog updatesFor laboratory research use only. Not for human or veterinary use. Not intended to diagnose, treat, cure, mitigate, or prevent disease.
Keep sealed, cold, dry, and protected from heat swings. Confirm product-specific storage on arrival.
Packed for transit stability with order support available for warm-weather routes.
Batch-linked certificate support is available through the documentation desk.
Research context
AOD-9604 research profile
AOD-9604 is a modified peptide based on the 176-191 region of human growth hormone. It is studied separately from full-length HGH because research questions generally focus on fragment-specific lipid-metabolism and adipocyte signaling rather than the complete growth-hormone receptor program. Common models examine lipolysis, lipogenesis, fat-cell metabolism, body-composition markers, and whether the fragment retains selected metabolic signals without reproducing all actions of the parent hormone. The evidence base includes laboratory, animal, and limited human research with mixed conclusions. It is best selected for GH-fragment comparisons, not as a substitute for HGH, GHRH analogs, or ghrelin-receptor secretagogues.
Proposed mechanism
A modified peptide derived from the 176-191 region of human growth hormone. The proposed mechanism is fragment-specific regulation of adipocyte lipid metabolism, including increased lipolysis and reduced lipogenesis, without reproducing the full growth-promoting signaling profile of intact HGH.
Effects reported in studies
- Cell and animal models reported increased fat breakdown, reduced fat synthesis, and reduced adiposity under selected experimental conditions.
- Human obesity studies did not consistently demonstrate a clinically convincing weight-loss effect.
- The literature does not establish that the fragment reproduces the broader anabolic or endocrine effects of full-length growth hormone.
Common research endpoints
Adipocyte lipolysis and lipogenesis, glycerol release, fat mass, body mass, glucose and IGF-1 markers, receptor independence, and comparison with intact HGH.
Evidence and limitations
Preclinical findings are stronger than the mixed human efficacy record. The proposed lipid effects remain model dependent and should not be presented as an established human outcome.
External reading
Literature for context—not product proof.
Third-party sources describe their own research materials and methods. They do not validate a specific Azure catalog batch.
Support and documentation
Questions about this product?
What documentation can I request before ordering?
Before ordering, contact support with the product name, selected format, andu2014if availableu2014an order or batch reference to request available batch-linked documentation.
What should I confirm before ordering?
Compare the product name, listed amount, physical form, storage note, price, and documentation route. When the order arrives, match the product and lot or batch reference to the order record and available documentation.